News for Eton Pharmaceuticals, Inc. (ETON)

On June 5, 2025, Sean Brynjelsen, President & CEO, 10% Owner of Eton Pharmaceuticals Inc (ETON), sold 210,000 shares of the company. Following this transaction,

Shares of Eton Pharmaceuticals Inc (ETON) fell 4.98% in mid-day trading on May 29. The stock reached an intraday low of $18.75, before recovering slightly to

H.C. Wainwright has increased its price target for Eton Pharmaceuticals (ETON) from $33 to $35, maintaining its Buy rating on the stock. This adjustment follows

Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals (ETON) has secured approval from the U.S. Food and Drug Administration for KHINDIVI Oral Solution, a new treatment designed for children ag

**media[639800]**

Eton Pharmaceuticals is able to buy orphan drugs from large pharma companies, where they are too small to matter. Read why ETON stock should be bought now.

Shares of Eton Pharmaceuticals Inc (ETON) surged 3.33% in mid-day trading on May 19. The stock reached an intraday high of $19.85, before settling at $19.56,

**media[626262]**

Revenue: $17.3 million in Q1 2025, up 117% from $8.0 million in Q1 2024.Product Sales: $14.0 million in Q1 2025, a 76% increase from $8.0 million in Q1 2024.Li

May 13, 2025 / 08:30PM GMTOperator Good afternoon, and welcome to the Eton Pharmaceuticals first-quarter 2025 financial results conference call. (Operator Instr

Key Takeaways: Eton Pharmaceuticals (ETON) is experiencing significant growth due to strategic acquisitions. Analysts predict a notable increase in stock

Q1 2025 revenue of $17.3 million, with product sales of $14.0 million, representing 76% growth over Q1 2024 and the 17th straight quarter of sequential product

Eton Pharmaceuticals (ETON) delivered earnings and revenue surprises of -22.22% and 6.71%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Eton Pharmaceuticals Inc (ETON) is set to release its Q1 2025 earnings on May 13, 2025. The consensus estimate for Q1 2025 revenue is $15.13 million, and the ea

DEER PARK, Ill., May 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (”œEton” or the ”œCompany”) ( ETON), an innovative pharmaceutical company fo

Eton Pharmaceuticals (ETON) will announce its Q1 2025 financial results on May 13, 2025. The company will host a conference call and webcast at 4:30 p.m

Eton Pharmaceuticals (ETON) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Eton Pharmaceuticals (ETON) stock in focus as the company out-licenses overseas rights for its hormone disorder therapy Increlex to Esteve Pharma. Read more here.